Christopher Gerner
Biochemiker,
Hochschullehrer
Hat mitgewirkt an:
-
A novel nanobody as therapeutics target for EGFR-positive colorectal cancer therapy: exploring the effects of the nanobody on SW480 cells using proteomics approach
-
New epithelial and mesenchymal cell lines from primary liver cancer to study cell interactions in hepatocarcinogenesis
-
An Anticancer Rhenium Tricarbonyl Targets Fe−S Cluster Biogenesis in Ovarian Cancer Cells
-
Plasticity of fibroblasts demonstrated by tissue-specific and function-related proteome profiling